Which manufacturer produces and develops adagrasib?

Adagrasib (Adagrasib) is developed and produced by Mirati Therapeutics. Mirati Therapeutics is a biopharmaceutical company dedicated to developing targeted cancer therapies, headquartered in the United States. The company focuses on targeted treatments for cancer-related gene mutations. Adagarasib is one of its most important drugs developed and is mainly used to treat KRAS G12C mutated non-small cell lung cancer (NSCLC) and other tumors.

Mirati TherapeuticsSince its establishment, it has focused on the development of targeted drugs targeting specific gene mutations. Its R&D pipeline includes a variety of targeted anti-cancer drugs. As one of the key drugs developed by the company, adagrasib uses the latest technology to inhibit the abnormal proliferation of cancer cells caused by KRAS G12C mutation. KRAS G12CMutation occurs frequently in a variety of tumors, so the development of adagrasib has attracted widespread attention in the field of cancer treatment.

The development of adagrasib began with in-depth research on KRAS mutations. KRAS G12C mutation is the most common type of mutation, especially in patients with non-small cell lung cancer. Mirati TherapeuticsThrough innovative drug design, it has successfully developed adagrasib, an oral small molecule drug specifically targeted for the KRAS G12C mutation. The drug has shown good efficacy in clinical trials, especially in patients with KRAS G12C mutated non-small cell lung cancer, achieving significant clinical responses.

Adagorasib has not yet been widely approved for marketing, but it has achieved positive results in multiple clinical trials. Mirati TherapeuticsDuring the global marketing process of adagrasib, we have maintained close cooperation with regulatory agencies in many countries and strive to obtain marketing approvals in more regions as soon as possible. Currently, adagrasib is being evaluated in multiple clinical studies to demonstrate its effectiveness in the treatment of various cancers related to KRAS G12C mutations (such as colorectal cancer, pancreatic cancer, etc.). With further accumulation of clinical data, adagrasib is expected to become one of the important drugs in the field of cancer treatment.

Through Mirati Therapeutics’s continued research and development and clinical trials, adagrasib has demonstrated strong therapeutic potential, especially providing new treatment options in some refractory cancer areas.

References：https://www.krazati.com/